Alendronate Sodium in the Management of Osteoporosis

References

• AdachiJDSaagKGDelmasPDTwo-year effects of alendronate on bone mineral density and vertebral fractures in patients receiving glucocorticoids: a randomised, double-blind, placebo-controlled extension trialArthritis Rheum2001442021111212161
   PubMed Web of Science ®Google Scholar
• BauerDCBlackDMGarneroPChanges in bone turnover and hip, non spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention TrialJ Bone Miner Res2004191250815231011
   PubMed Web of Science ®Google Scholar
• BjarnassonNHAlexandersenPChristiansenCNumber of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independentBone2002306374211934658
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesLancet19963481535418950879
   PubMed Web of Science ®Google Scholar
• BlackDMThompsonDEBauerDCFracture risk reduction with alendronate in women with osteoporosis: The fracture intervention trialJ Clin Endocrinol Metab20008541182411095442
   PubMed Web of Science ®Google Scholar
• BlackDMGreenspanSLEnsrudKEThe effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisN Engl J Med200334912071514500804
   PubMed Web of Science ®Google Scholar
• BlackDMBilezikianJPEnsrudKEOne year of alendronate after one year of parathyroid hormone (1-84) for osteoporosisN Engl J Med20053535556516093464
   PubMed Web of Science ®Google Scholar
• BoivinGYChavassieuxPMSantoraACAlendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic womenBone2000276879411062357
   PubMed Web of Science ®Google Scholar
• BoneHGDownsRWJrTucciJRDose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study CentresJ Clin Endocrinol Metab199782265748989272
   PubMed Web of Science ®Google Scholar
• BoneHGHoskingDDevogelaerJ-PTen years experience with alendronate for osteoporosis in postmenopausal womenN Engl J Med200435011899915028823
   PubMed Web of Science ®Google Scholar
• CanalisEBilezikianJPAngeliAPerspectives on glucocorticoid-induced osteoporosisBone2004345939815050888
   PubMed Web of Science ®Google Scholar
• CosmanFNievesJHerbertJHigh-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeletonJ Bone Miner Res1994910971057942157
   PubMed Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDEEffect of alendronate on risk of fracture in women with low bone density but without vertebral fracturesJAMA19982802077829875874
   PubMed Web of Science ®Google Scholar
• DelmasPDLiZCooperCRelationship between changes in bone mineral density and fracture risk reduction with anti-resorptive drugs: some issues with meta-analysesJ Bone Miner Res200419330714969404
   PubMed Web of Science ®Google Scholar
• DelmasPDSeemanEChanges in bone mineral density explain little of the reductionin vertebral or nonvertebral fracture risk with anti-resorptive therapyBone2004345990415050889
   PubMed Web of Science ®Google Scholar
• DohertyDSandersKKotowiczMLifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal womenOsteoporos Int200112162311305078
   PubMed Web of Science ®Google Scholar
• EnsrudDEBlackDMPalermoLTreatment with alendronate prevents fractures in women at highest risk. Results from the Fracture Intervention TrialArch Intern Med19971572617249531231
   PubMed Web of Science ®Google Scholar
• EnsrudKEBarrett-ConnorELSchwartzARandomized trial effects of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial Long-term ExtensionJ Bone Miner Res20041912596915231012
   PubMed Web of Science ®Google Scholar
• FinkelsteinJSHayesAHunslemannJLThe effects of parathyroid hormone, alendronate, or both in men with osteoporosisN Engl J Med200334912162614500805
   PubMed Web of Science ®Google Scholar
• GarneroPHausherrEChapuyMCMarkers of bone resorption predict hip fractures in elderly women:The EPIDOS prospective studyJ Bone Miner Res199611153188889854
   PubMed Web of Science ®Google Scholar
• GarneroPSornay-RenduEClaustratBBiochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFLEY studyJ Bone Miner Res20001515263610934651
   PubMed Web of Science ®Google Scholar
• GonnelliSRottoliPCepollaroCPrevention of corticosteroid–induced osteoporosis with alendronate in sarcoid patientsCalcif Tissue Int19976138259351879
   PubMed Web of Science ®Google Scholar
• GreenspanSLParkerRAFergusonLEarly changes in biochemical markers of bone turnover predict the long term response to alendronate in representative elderly women: A randomized clinical trialJ Bone Miner Res199813143189738515
   PubMed Web of Science ®Google Scholar
• HeaneyRPYatesAJSantoraACBisphosphonate effects and the bone remodelling transientJ Bone Miner Res1997121143519258743
   PubMed Web of Science ®Google Scholar
• HochbergMCGreenspanSWasnichRDChanges in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agentsJ Clin Endocrinol Metab20028715869211932287
   PubMed Web of Science ®Google Scholar
• HoskingDAdamiSFelsenbergDComparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomized placebo controlled studyCurr Med Res Opin2003193839413678475
   PubMed Web of Science ®Google Scholar
• HoskingDChilversCEDChristiansenCPrevention of bone loss with alendronate in postmenopausal women under 60 years of ageNew Engl J Med1998338485929443925
   PubMed Web of Science ®Google Scholar
• KanisJAOdenAJohnellOUncertain future of trials in osteoporosisOsteoporos Int200213443912107656
   PubMed Web of Science ®Google Scholar
• KlozbuecherCMRossPDLandsmanPBPatients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesisJ Bone Miner Res2000157213910780864
   PubMed Web of Science ®Google Scholar
• KurlandESHellerSLDiamondBThe importance of bisphosphonate therapy in maintaining bone mass in men after therapy with Teriparatide (human parathyroid hormone 1–34)Osteoporos Int200415992715175844
   PubMed Web of Science ®Google Scholar
• LevisSQuandtSAThompsonDAlendronate reduces the risk of multiple symptomatic fractures: results from the Fracture Intervention TrialJ Am Geriatr Soc2002504091511943033
   PubMed Web of Science ®Google Scholar
• LibermanUAWeissSRBrollJEffect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosisN Engl J Med19953331437437477143
   PubMed Web of Science ®Google Scholar
• LindsayRNievesJFormicaCRandomised controlled study of effect of Parathyroid Hormone on vertebral bone mass and fracture incidents amongst post menopausal women on oestrogen with osteoporosisLancet199735055059284777
   PubMed Web of Science ®Google Scholar
• LindsayRCosmanFLoboRAAddition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trialJ Clin Endocrinol Metab19998430768110487668
   PubMed Web of Science ®Google Scholar
• LindsayRScheeleWHNeerRSustained vertebral fracture risk reduction after withdrawal of Teriparatide in postmenopausal women with osteoporosisArch Intern Med200416420243015477438
   PubMed Web of Science ®Google Scholar
• LookerACJohnstonCCJrWahnerHWPrevalence of low femoral bone density in older U.S women from NHANES IIIJ Bone Miner Res199510796027639115
   PubMed Web of Science ®Google Scholar
• LuckeyMKaganRGreenspanSOnce-weekly alendronate 70mg and raloxifene 60mg daily in the treatment of postmenopausal osteoporosisMenopause2004114051515243278
   PubMed Web of Science ®Google Scholar
• Mc CombsJSThiebaudPMcLaughlin-MileyCCompliance with drug therapies for the treatment and prevention of osteoporosisMaturitas2004482718715207894
   PubMed Web of Science ®Google Scholar
• McClungMRWasnichRDHoskingDJPrevention of postmenopausal bone loss: six year results from the Early Postmenopausal Intervention Cohort studyJ Clin Endocrinol Metab20048948798515472179
   PubMed Web of Science ®Google Scholar
• MeltonLJIIIChrischillesEACooperCPerspective: How many women have osteoporosis?J Bone Miner Res199271005101414493
   PubMed Web of Science ®Google Scholar
• MeltonLJIIIAtkinsonEJO’ConnorMKBone density and fracture risk in menJ Bone Miner Res1998131915239844110
   PubMed Web of Science ®Google Scholar
• NeerRMArnaudCDZanchettaJREffect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med200134414344111346808
   PubMed Web of Science ®Google Scholar
• NevittMCRossPDPalermoLAssociation of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fracturesBone1999256131910574584
   PubMed Web of Science ®Google Scholar
• NevittMCThompsonDEBlackDMEffect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing fracturesArch Intern Med2000160778510632308
   PubMed Web of Science ®Google Scholar
• OdvinaCVZerwekhJERaoDSSeverely suppressed bone turnover: a potential complication of alendronate therapyJ Clin Endocrinol Metab200590129430115598694
   PubMed Web of Science ®Google Scholar
• OrwollEEttinghamMViceSAlendronate for the treatment of osteoporosis in menN Engl J Med20003436041010979796
   PubMed Web of Science ®Google Scholar
• OrwollESKleinRMarcusRFeldmanDKelseyJOsteoporosis in men. Epidemiology, pathophysiology, and clinical characterizationOsteoporosis20012nd edSan DiegoAcad Pr10349
   Google Scholar
• PatschanDLoddenkemperKButtgereitFMolecular mechanisms of glucocorticoid-induced osteoporosisBone20012949850511728918
   PubMed Web of Science ®Google Scholar
• PolsHAPFelsenbergDHanleyDAMultinational, placebo controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT studyOsteoporos Int19999461810550467
   PubMed Web of Science ®Google Scholar
• RavnPBidstrupMWasnichRDAlendronate and estrogen-progestin in the long-term prevention of bone loss: Four year results from the Early Postmenopausal Intervention Cohort studyAnn Intern Med19991319354210610644
   PubMed Web of Science ®Google Scholar
• RingeJDFaberHDorstAAlendronate treatment of established primary steoporosis in men: results of a 2-year prospective studyJ Clin Endocrinol Metab20018652525511701687
   PubMed Web of Science ®Google Scholar
• RittmasterRSBologneseMEttingerMPEnhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronateJ Clin Endocrinol Metab20008521293410852440
   PubMed Web of Science ®Google Scholar
• RizzoliRGreenspanSLBoneHGTwo year results of once weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosisJ Bone Miner Res20021719889612412806
   PubMed Web of Science ®Google Scholar
• RosenCJHochbergMCBonnickSLTreatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausalosteoporosis: a randomized double-blind studyJ Bone Miner Res2005201415115619680
   PubMed Web of Science ®Google Scholar
• SaagKGEmkeyRSchnitzerTJAlendronate for the prevention and treatment of glucocorticoid-induced osteoporosisN Engl J Med199833929299682041
   PubMed Web of Science ®Google Scholar
• SambrookPNGeusensPRibotCAlendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density:results of the EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) internationalJ Int Med200425550311
   PubMed Web of Science ®Google Scholar
• SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10mg daily in the treatment of osteoporosisAging Clin Exp Res200012112
   Web of Science ®Google Scholar
• ToninoRPMeunierPJEmkeyRSkeletal benefits of alendronate; 7-year treatment of postmenopausal osteoporotic womenJ Clin Endocrinol Metab20008531091510999794
   PubMed Web of Science ®Google Scholar
• ToninoRPSantoraACRossPDSafety of long term alendronateJ Clin Endocrinol Metab2001861835611297626
   PubMed Web of Science ®Google Scholar
• Van StaaTPLeufkensHGMAbenhaimLUse of oral corticosteroids and risk of fracturesJ Bone Miner Res200015993100010841167
   PubMed Web of Science ®Google Scholar
• Van StaaTPLeufkensHGMCooperCThe epidemiology of corticosteroid-induced osteoporosisOsteoporos Int2002137778712378366
   PubMed Web of Science ®Google Scholar
• WalshLJWongCAPringleMUse of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional studyBMJ199631334468760745
   PubMed Web of Science ®Google Scholar
• WasnichRDMillerPDAntifracture efficacy of antiresorptive agents are related to changes in bone densityJ Clin Endocrinol Metab200085231610634392
   PubMed Web of Science ®Google Scholar
• WasnichRDBaggerYZHoskingDJChanges in bone density and turnover after alendronate or estrogen withdrawalMenopause2004116223015545790
   PubMedGoogle Scholar
• WeinsteinRSGlucocorticoid-induced osteoporosisRev Endocr Metab Disord20012657311708295
   PubMedGoogle Scholar